EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Feasibility of a 12-Week, Therapist-Independent, Smartphone-Based Biofeedback Treatment for Episodic Migraine in Adults: Single-Center, Open-Label, 1-Armed Trial

Amalie Christine Poole iD, Ingunn Grøntveit Winnberg iD, Melanie Rae Simpson iD, Anker Stubberud iD, Kjersti Grøtta Vetvik iD, Marte-Helene Bjørk iD, Lise Rystad Øie iD, Petter Holmboe iD, Alexander Olsen iD, Erling Tronvik iD, Tore Wergeland iD

JMIR Human Factors · 2025

DOI: 10.2196/59622 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JMIR Human Factors, 2025. Verfasst von Amalie Christine Poole und 10 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Headache Research (NorHead), NTNU Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Migraine Disorders, Smartphone, Biofeedback, Psychology, Mobile Applications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biofeedback is an established treatment principle for migraine, but home-based therapy with proven efficacy is not available.

Objective

This study aims to assess the feasibility, usability, and safety of 12 weeks of daily use of a novel medical device (Cerebri; Nordic Brain Tech AS) for therapist-independent multimodal biofeedback preventative treatment in adults with episodic migraine.

Methods

In this open-label, one-armed trial, 20 adult participants with episodic migraine used Cerebri for 12 weeks. The primary outcome was the feasibility of the Cerebri system, measured by the level of adherence to daily biofeedback and electronic headache diary (eDiary) entries. Secondary outcomes were safety, usability, and efficacy.

Results

Initial adherence to biofeedback was high (16/20, 80% in weeks 1‐4), declining to 20% (4/20) by weeks 9‐12. eDiary adherence remained high (15/20, 75% in weeks 9‐12). Reduction in migraine days was not significant (–0.6, 95% CI –2.4 to 1.1 days; P =.47). App usability was impacted by software issues. No safety concerns were reported.

Conclusions

Cerebri demonstrates potential in self-managed migraine treatment, with strong initial engagement and high safety. Usability issues, including technical bugs, were identified as the most important modifiable cause for the decline in adherence. This highlights the need for further app refinement to sustain user engagement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersSmartphoneBiofeedback, PsychologyMobile ApplicationsHumansAdultMaleFemaleFeasibility StudiesMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

adherenceappbehavioral therapybiofeedbackcomplementaryfeasibilityheadachemHealthmigrainemobile healthmobile phoneneurologypsychologypsychophysiologysafety

Autor:innen und Institutionen

  • Norwegian Centre for Headache Research (NorHead), NTNU Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Neurology and Neurophysiology, St. Olavs University Hospital, Trondheim, Norway, 47 73 59 20 20.
  • Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Neuromedicine and Movement Science, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
  • Department of Neurology, Haukeland University Hospital, Bergen, Norway.

ORCID-Profile: Amalie Christine Poole, Ingunn Grøntveit Winnberg, Melanie Rae Simpson, Anker Stubberud, Kjersti Grøtta Vetvik, Marte-Helene Bjørk, Lise Rystad Øie, Petter Holmboe, Alexander Olsen, Erling Tronvik, Tore Wergeland

Zitieren

APA

Poole, A. C., Winnberg, I. G., Simpson, M. R., Stubberud, A., Vetvik, K. G., Bjørk, M. H., Øie, L. R., Holmboe, P., Olsen, A., Tronvik, E., & Wergeland, T. (2025). Feasibility of a 12-Week, Therapist-Independent, Smartphone-Based Biofeedback Treatment for Episodic Migraine in Adults: Single-Center, Open-Label, 1-Armed Trial. JMIR Human Factors. https://doi.org/10.2196/59622

Vancouver

Poole AC, Winnberg IG, Simpson MR, Stubberud A, Vetvik KG, Bjørk MH, et al. Feasibility of a 12-Week, Therapist-Independent, Smartphone-Based Biofeedback Treatment for Episodic Migraine in Adults: Single-Center, Open-Label, 1-Armed Trial. JMIR Human Factors. 2025. doi:10.2196/59622

BibTeX
@article{Poole2025,
  author = {Poole, Amalie Christine and Winnberg, Ingunn Grøntveit and Simpson, Melanie Rae and Stubberud, Anker and Vetvik, Kjersti Grøtta and Bjørk, Marte-Helene and Øie, Lise Rystad and Holmboe, Petter and Olsen, Alexander and Tronvik, Erling and Wergeland, Tore},
  title = {Feasibility of a 12-Week, Therapist-Independent, Smartphone-Based Biofeedback Treatment for Episodic Migraine in Adults: Single-Center, Open-Label, 1-Armed Trial},
  journal = {JMIR Human Factors},
  year = {2025},
  doi = {10.2196/59622}
}
Kostenlos starten →